-
1
-
-
34547754569
-
NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status
-
Osawa Y, Osawa K, Miyaishi A, et al. NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev, 2007, 8(1): 103-108.
-
(2007)
Asian Pac J Cancer Prev
, vol.8
, Issue.1
, pp. 103-108
-
-
Osawa, Y.1
Osawa, K.2
Miyaishi, A.3
-
2
-
-
0035895504
-
Human DNA repair genes
-
Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science, 2001, 291(5507): 1284-1289.
-
(2001)
Science
, vol.291
, Issue.5507
, pp. 1284-1289
-
-
Wood, R.D.1
Mitchell, M.2
Sgouros, J.3
-
3
-
-
62549137858
-
MUTYH Gln324His gene polymorphism and genetic susceptibility for lung cancer in a Japanese population
-
Miyaishi A, Osawa K, Osawa Y, et al. MUTYH Gln324His gene polymorphism and genetic susceptibility for lung cancer in a Japanese population. J Exp Clin Cancer Res, 2009, 28: 10.
-
(2009)
J Exp Clin Cancer Res
, vol.28
, pp. 10
-
-
Miyaishi, A.1
Osawa, K.2
Osawa, Y.3
-
4
-
-
33745186494
-
Pharmacogenetics approach to therapeutics
-
Koo SH, Lee EJ. Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol, 2006, 33(5-6): 525-532.
-
(2006)
Clin Exp Pharmacol Physiol
, vol.33
, Issue.5-6
, pp. 525-532
-
-
Koo, S.H.1
Lee, E.J.2
-
5
-
-
0037050354
-
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
-
DOI 10.1056/NEJMoa003034
-
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002, 346(2): 85-91. (Pubitemid 34438898)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.2
, pp. 85-91
-
-
Noda, K.1
Nishiwaki, Y.2
Kawahara, M.3
Negoro, S.4
Sugiura, T.5
Yokoyama, A.6
Fukuoka, M.7
Mori, K.8
Watanabe, K.9
Tamura, T.10
Yamamoto, S.11
Saijo, N.12
-
6
-
-
45849135654
-
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients
-
Sai K, Saito Y, Fukushima-Uesaka H, et al. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol, 2008, 62(3): 529-537.
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, Issue.3
, pp. 529-537
-
-
Sai, K.1
Saito, Y.2
Fukushima-Uesaka, H.3
-
7
-
-
0034892379
-
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
-
Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res, 2001, 7(8): 2182-2194.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.8
, pp. 2182-2194
-
-
Mathijssen, R.H.1
Van Alphen, R.J.2
Verweij, J.3
-
8
-
-
0036148810
-
Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan
-
DOI 10.1097/00007691-200202000-00018
-
Ando Y, Ueoka H, Sugiyama T, et al. Polymorphisms of UDP- glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit, 2002, 24(1): 111-116. (Pubitemid 34106739)
-
(2002)
Therapeutic Drug Monitoring
, vol.24
, Issue.1
, pp. 111-116
-
-
Ando, Y.1
Ueoka, H.2
Sugiyama, T.3
Ichiki, M.4
Shimokata, K.5
Hasegawa, Y.6
-
9
-
-
33748925080
-
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
-
DOI 10.1111/j.1349-7006.2006.00321.x
-
Araki K, Fujita K, Ando Y, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci, 2006, 97(11): 1255-1259. (Pubitemid 44430653)
-
(2006)
Cancer Science
, vol.97
, Issue.11
, pp. 1255-1259
-
-
Araki, K.1
Fujita, K.-I.2
Ando, Y.3
Nagashima, F.4
Yamamoto, W.5
Endo, H.6
Miya, T.7
Kodama, K.8
Narabayashi, M.9
Sasaki, Y.10
-
10
-
-
0032767352
-
UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: Relationships to serum bilirubin concentrations
-
Lampe JW, Bigler J, Horner NK, et al. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics, 1999, 9(3): 341-349. (Pubitemid 29376378)
-
(1999)
Pharmacogenetics
, vol.9
, Issue.3
, pp. 341-349
-
-
Lampe, J.W.1
Bigler, J.2
Horner, N.K.3
Potter, J.D.4
-
11
-
-
0034671387
-
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
-
Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res, 2000, 60(24): 6921-6926. (Pubitemid 32059164)
-
(2000)
Cancer Research
, vol.60
, Issue.24
, pp. 6921-6926
-
-
Ando, Y.1
Saka, H.2
Ando, M.3
Sawa, T.4
Muro, K.5
Ueoka, H.6
Yokoyama, A.7
Saitoh, S.8
Shimokata, K.9
Hasegawa, Y.10
-
12
-
-
9144265660
-
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
-
Font A, Sánchez JM, Tarón M, et al Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs, 2003, 21(4): 435-443.
-
(2003)
Invest New Drugs
, vol.21
, Issue.4
, pp. 435-443
-
-
Font, A.1
Sánchez, J.M.2
Tarón, M.3
-
13
-
-
34547788826
-
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients
-
Jada SR, Lim R, Wong CI, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci, 2007, 98(9): 1461-1467.
-
(2007)
Cancer Sci
, vol.98
, Issue.9
, pp. 1461-1467
-
-
Jada, S.R.1
Lim, R.2
Wong, C.I.3
-
14
-
-
33744804311
-
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
-
Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol, 2006, 24(15): 2237-2244.
-
(2006)
J Clin Oncol
, vol.24
, Issue.15
, pp. 2237-2244
-
-
Han, J.Y.1
Lim, H.S.2
Shin, E.S.3
-
15
-
-
34250665419
-
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer
-
DOI 10.1007/s00280-006-0396-1
-
Fujita K, Ando Y, Nagashima F, et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol, 2007, 60(4): 515-522. (Pubitemid 47084262)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.60
, Issue.4
, pp. 515-522
-
-
Fujita, K.-I.1
Ando, Y.2
Nagashima, F.3
Yamamoto, W.4
Eodo, H.5
Araki, K.6
Kodama, K.7
Miya, T.8
Narabayashi, M.9
Sasaki, Y.10
-
16
-
-
37549028363
-
Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer
-
Han JY, Lim HS, Shin ES, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 2008, 59(1): 69-75.
-
(2008)
Lung Cancer
, vol.59
, Issue.1
, pp. 69-75
-
-
Han, J.Y.1
Lim, H.S.2
Shin, E.S.3
-
17
-
-
34848899579
-
Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: A homozygote for the SLCO1B1*15 allele
-
DOI 10.1097/FTD.0b013e3181357364, PII 0000769120071000000020
-
Takane H, Miyata M, Burioka N, et al. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit, 2007, 29(5): 666-668. (Pubitemid 47494070)
-
(2007)
Therapeutic Drug Monitoring
, vol.29
, Issue.5
, pp. 666-668
-
-
Takane, H.1
Miyata, M.2
Burioka, N.3
Kurai, J.4
Fukuoka, Y.5
Suyama, H.6
Shigeoka, Y.7
Otsubo, K.8
Ieiri, I.9
Shimizu, E.10
-
18
-
-
34250825286
-
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
-
Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 2007, 110(1): 138-147.
-
(2007)
Cancer
, vol.110
, Issue.1
, pp. 138-147
-
-
Han, J.Y.1
Lim, H.S.2
Yoo, Y.K.3
-
19
-
-
0029618266
-
DNA repair in humans
-
Sancar A. DNA repair in humans. Annu Rev Genet, 1995, 29: 69-105.
-
(1995)
Annu Rev Genet
, vol.29
, pp. 69-105
-
-
Sancar, A.1
-
20
-
-
2342616723
-
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
-
DOI 10.1016/j.lungcan.2003.11.019, PII S0169500203006342
-
Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 2004, 44(3): 311-316. (Pubitemid 38609439)
-
(2004)
Lung Cancer
, vol.44
, Issue.3
, pp. 311-316
-
-
Ryu, J.-S.1
Hong, Y.-C.2
Han, H.-S.3
Lee, J.-E.4
Kim, S.5
Park, Y.-M.6
Kim, Y.-C.7
Hwang, T.-S.8
-
21
-
-
4444256594
-
Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer
-
DOI 10.1093/annonc/mdh319
-
Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol, 2004, 15(8): 1194-1203. (Pubitemid 39199306)
-
(2004)
Annals of Oncology
, vol.15
, Issue.8
, pp. 1194-1203
-
-
Isla, D.1
Sarries, C.2
Rosell, R.3
Alonso, G.4
Domine, M.5
Taron, M.6
Lopez-Vivanco, G.7
Camps, C.8
Botia, M.9
Nunez, L.10
Sanchez-Ronco, M.11
Sanchez, J.J.12
Lopez-Brea, M.13
Barneto, I.14
Paredes, A.15
Medina, B.16
Artal, A.17
Lianes, P.18
-
22
-
-
4143051317
-
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
-
DOI 10.1158/1078-0432.CCR-04-0247
-
Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 2004, 10(15): 4939-4943. (Pubitemid 39099767)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.15
, pp. 4939-4943
-
-
Zhou, W.1
Gurubhagavatula, S.2
Liu, G.3
Park, S.4
Neuberg, D.S.5
Wain, J.C.6
Lynch, T.J.7
Su, L.8
Christiani, D.C.9
-
23
-
-
33645298447
-
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
-
de las Peñas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol, 2006, 17(4): 668-675.
-
(2006)
Ann Oncol
, vol.17
, Issue.4
, pp. 668-675
-
-
De Las Peñas, R.1
Sanchez-Ronco, M.2
Alberola, V.3
-
24
-
-
41549095093
-
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
-
Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res, 2008, 14(6): 1797-1803.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.6
, pp. 1797-1803
-
-
Tibaldi, C.1
Giovannetti, E.2
Vasile, E.3
-
25
-
-
20044368468
-
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
-
DOI 10.1158/1078-0432.CCR-04-1953
-
Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res, 2005, 11(4): 1534-1538. (Pubitemid 40315237)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.4
, pp. 1534-1538
-
-
Suk, R.1
Gurubhagavatula, S.2
Park, S.3
Zhou, W.4
Su, L.5
Lynch, T.J.6
Wain, J.C.7
Neuberg, D.8
Liu, G.9
Christiani, D.C.10
-
26
-
-
66449119340
-
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer
-
Shanghai
-
Feng J, Sun X, Sun N, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai), 2009, 41(5): 429-435.
-
(2009)
Acta Biochim Biophys Sin
, vol.41
, Issue.5
, pp. 429-435
-
-
Feng, J.1
Sun, X.2
Sun, N.3
-
27
-
-
34548161176
-
No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: A meta-analysis
-
DOI 10.1038/sj.ejhg.5201855, PII 5201855
-
Li Y, Gu S, Wu Q, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet, 2007, 15(9): 967-973. (Pubitemid 47308473)
-
(2007)
European Journal of Human Genetics
, vol.15
, Issue.9
, pp. 967-973
-
-
Li, Y.1
Gu, S.2
Wu, Q.3
Li, Y.4
Fu, X.5
Mao, Y.6
Huang, Y.7
Xie, Y.8
-
28
-
-
4344567395
-
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
-
DOI 10.1200/JCO.2004.08.067
-
Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 2004, 22(13): 2594-2601. (Pubitemid 41103746)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.13
, pp. 2594-2601
-
-
Gurubhagavatula, S.1
Liu, G.2
Park, S.3
Zhou, W.4
Su, L.5
Wain, J.C.6
Lynch, T.J.7
Neuberg, D.S.8
Christiani, D.C.9
-
29
-
-
34249812370
-
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
-
DOI 10.1158/1078-0432.CCR-06-2543
-
Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res, 2007, 13(10): 2876-2881. (Pubitemid 46849561)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.10
, pp. 2876-2881
-
-
Giachino, D.F.1
Ghio, P.2
Regazzoni, S.3
Mandrile, G.4
Novello, S.5
Selvaggi, G.6
Gregori, D.7
Demarchi, M.8
Scagliotti, G.V.9
-
30
-
-
34447303456
-
Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism
-
DOI 10.1200/JCO.2006.06.7405
-
Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cybdine deaminase polymorphism. J Clin Oncol, 2007, 25(1): 32-42. (Pubitemid 350003048)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.1
, pp. 32-42
-
-
Sugiyama, E.1
Kaniwa, N.2
Kim, S.-R.3
Kikura-Hanajiri, R.4
Hasegawa, R.5
Maekawa, K.6
Saito, Y.7
Ozawa, S.8
Sawada, J.-I.9
Kamatani, N.10
Furuse, J.11
Ishii, H.12
Yoshida, T.13
Ueno, H.14
Okusaka, T.15
Saijo, N.16
-
31
-
-
33847323129
-
Epidermal growth factor receptor mutations in lung cancer
-
DOI 10.1038/nrc2088, PII NRC2088
-
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007, 7(3): 169-181. (Pubitemid 46316032)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.3
, pp. 169-181
-
-
Sharma, S.V.1
Bell, D.W.2
Settleman, J.3
Haber, D.A.4
-
32
-
-
58949098405
-
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer
-
Tiseo M, Capelletti M, De Palma G, et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol, 2008, 3(10): 1104-1111.
-
(2008)
J Thorac Oncol
, vol.3
, Issue.10
, pp. 1104-1111
-
-
Tiseo, M.1
Capelletti, M.2
De Palma, G.3
-
33
-
-
67349206986
-
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
-
Huang CL, Yang CH, Yeh KH, et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer, 2009, 64(3): 346-351.
-
(2009)
Lung Cancer
, vol.64
, Issue.3
, pp. 346-351
-
-
Huang, C.L.1
Yang, C.H.2
Yeh, K.H.3
-
34
-
-
11244319884
-
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
-
Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res, 2005, 65(1): 46-53. (Pubitemid 40070794)
-
(2005)
Cancer Research
, vol.65
, Issue.1
, pp. 46-53
-
-
Liu, W.1
Innocenti, F.2
Wu, M.H.3
Desai, A.A.4
Dolan, M.E.5
Cook Jr., E.H.6
Ratain, M.J.7
-
35
-
-
40949096067
-
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
-
Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J, 2008, 8(2): 129-138.
-
(2008)
Pharmacogenomics J
, vol.8
, Issue.2
, pp. 129-138
-
-
Liu, G.1
Gurubhagavatula, S.2
Zhou, W.3
-
36
-
-
34247477205
-
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
-
DOI 10.1371/journal.pmed.0040125
-
Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med, 2007, 4(4): e125. (Pubitemid 46658773)
-
(2007)
PLoS Medicine
, vol.4
, Issue.4
, pp. 715-727
-
-
Nomura, M.1
Shigematsu, H.2
Li, L.3
Suzuki, M.4
Takahashi, T.5
Estess, P.6
Siegelman, M.7
Feng, Z.8
Kato, H.9
Marchetti, A.10
Shay, J.W.11
Spitz, M.R.12
Wistuba, I.I.13
Minna, J.D.14
Gazdar, A.F.15
|